The average P/S ratio for XTLB's competitors is 25.13, providing a benchmark for relative valuation. X T L Biopharmaceuticals Ltd Corp (XTLB) exhibits a P/S ratio of 0.03, which is -99.87% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.